•   
  •   
  •   

Health & Fit US drug authority was controversial Alzheimer drug to

11:05  08 june  2021
11:05  08 june  2021 Source:   kleinezeitung.at

Alzheimer: DonaneMab, the new hope of effective treatment?

 Alzheimer: DonaneMab, the new hope of effective treatment? © Adobe Stock Alzheimer: DonaneMab, the new hope of effective treatment? A new clinical study of Phase 2 reveals that the donaneMab would be effective in reducing the progression of cognitive decline in patients at the early stage of Alzheimer's disease. This is a new hope of treatment against Alzheimer's disease. A phase 2 clinical trial has just been published in the New England Medical Journal of Medicine.

Audio on Demand. US approves controversial Alzheimer 's drug . US health officials have approved the first new drug for Alzheimer 's disease in nearly 20 years -- despite warnings from independent advisers that the treatment, made by Biogen, has NOT been shown to SLOW the brain-destroying illness. Regulators says it's the only drug that can treat the disease, rather than manage its symptoms.

It is the only drug approved by US regulators to treat the underlying cause of the disease, the build-up of fatty plaque in the brain. Clinical trials of the new drug , developed by Biogen Inc, showed a reduction in the plaque, thus helping to slow mental decline. However, the FDA’s approval of the drug is controversial because of warnings from independent experts that the treatment does not work. The FDA is requiring Biogen to conduct additional clinical trials to verify the drug ’s expected benefits. Groups representing Alzheimer ’s patients and their families said any new therapy – even one of small

The active substance ADUCANUMAB was the first novel treatment method against the neurodegenerative disease that has been admitted since 2003, the FDA announced on Monday. The drug developed by the US Biotechnology Group Biogen is to be given to patients with Alzheimer in the early stage as a monthly infusion and stop the degradation of mental power.

Bild: (c) AP (David A. White) © Picture: (c) AP (David A. White) Image: (c) AP (David A. White)

How well Aducanumab works, is controversial: In 2019, two clinical trials for testing Aucanumab, under the Name Aduhelm is marketed because lacking view of success has been canceled. An internal advisory body of the FDA had spoken against the approval.

Alzheimer: 12 minutes of meditation per day Reduce your risks

 Alzheimer: 12 minutes of meditation per day Reduce your risks © iStock Alzheimer: 12 minutes of meditation per day Reduces your risks According to an American study, the regular practice of meditation positively influences the health of the brain. People who do this exercise 12 minutes a day reduce their risk of developing Alzheimer's disease. How to avoid the cognitive decline ? The solutions are simple and varied: stay active intellectually, eat healthy or sleep enough.

Biogen's drug had been hailed by patient advocates and some neurologists eager to have an effective option for patients with the lethal disease. Other doctors said clinical trial results were inconsistent and more proof was needed. It makes the drug available to patients while requiring the company to do more research to prove its benefit," said Dr. Howard Fillit, chief science officer of the Alzheimer ’s Drug Discovery Foundation. Some trial patients experienced potentially dangerous brain swelling. The FDA advised that patients who experience the side effect should be monitored but not necessarily taken off

The first new drug against Alzheimer 's disease in nearly two decades received a conditional and controversial green light from U . S . drug regulators on Monday. The U . S . Food and Drug Administration approved biotech company Biogen's antibody drug aducanumab. The drug reduces the amyloid plaques that riddle the brains of Alzheimer 's patients. But the approval drew sharp criticism from experts who note that the company has not proved that it slows the debilitating cognitive decline in patients with the disease. The FDA will require Biogen to continue testing the drug after it is released

"We are very conscious of attention around this approval," said it now from the FDA. It was concluded that the benefits of Aducanumab is greater than the risks. The drug will now be further observed, and the manufacturer must make further studies. "If the active substance is not as intended as intended, we can take steps to get it back from the market."

Medium Bring No Healing

"These are good news for Alzheimer patients," said Alzheimer expert Ronald Petersen from the Mayo Clinic and spoke of a "special day". He pointed out, however, that the remedy does not bring healing. "There is hope that this slows down the progression of the disease." Biogen can expect a billion business: Guggenheim Analyst Suneja drews the drug a top sales potential of at least ten billion dollars.

Wife chronicles heartbreaking moments as caregiver for husband with Alzheimer's

  Wife chronicles heartbreaking moments as caregiver for husband with Alzheimer's Meet the Andover, Connecticut woman caring for a husband who sometimes doesn't recognize her as his wife.In 2018 at age 53, Peter was diagnosed with early onset Alzheimer's, and Lisa, his wife and full-time caretaker, has been by his side since.

Biogen's drug has been hailed by patient groups and some neurologists eager for an effective option to treat the lethal disease, but trial results have been inconsistent. One Phase III aducanumab study resulted in a statistically significant 23% benefit at slowing declines in cognition and daily function So far, Alzheimer ’s disease is one puzzle the medical community has been unable to solve, and there are currently no available treatments to halt the progress of the memory obliterating disease. That could all change today, when Biogen’s (BIIB) controversial Alzheimer ’s drug aducanumab’s fate is decided

Biogen's drug has been hailed by patient groups and some neurologists eager for an effective option to treat the lethal disease, but trial results have been inconsistent. One Phase III aducanumab study resulted in a statistically significant 23% benefit at slowing declines in cognition and daily function We conclude that aducanumab achieves the standard of meaningful efficacy with adequate safety," six prominent Alzheimer 's experts, including lead author Dr. Jeffrey Cummings, director of the University of Nevada Las Vegas Chambers-Grundy Center for Transformative Neuroscience, wrote last month in

ADUCANUMA is aimed at eliminating beta-amyloid - one of the two characteristic protein deposits for Alzheimer - from the brains of patients at an early stage of the disease. According to the FDA, the clinical trials with the remedy to be marketed under the name of Aduhelm showed a significant reduction in deposits. In some patients, however, a potentially hazardous brain swelling occurred.

So far, there is no effective therapy for the rapidly progressive dementia disease, which accumulate in the brain of the affected protein clumps that damage the nerve cells. Numerous pharmaceuticals had to cope with failures in this field of research. Current medicines can only relieve the symptoms.

What Brain Experts Think About the Controversial New Alzheimer’s Drug .
TODAY nutritionist Joy Bauer joins TODAY to talk about the nutritional breakdown of dairy milk, soy milk, almond milk, oat milk, hemp milk and banana milk.

usr: 0
This is interesting!